MTM Diabetes & Cardiovascular Pharmacotherapy 3

Question 1

A patient with T2DM and heart failure with reduced ejection fraction (HFrEF) is on an SGLT2 inhibitor. Which additional medication class has been shown to reduce mortality in HFrEF?

Accepted Answer

Sacubitril/valsartan (ARNI)

Answer

Sacubitril/valsartan is a guideline-directed therapy for HFrEF that reduces mortality and is appropriate alongside SGLT2 inhibitors.

Question 2

Which DPP-4 inhibitor has been shown to increase the risk of hospitalization for heart failure in the SAVOR-TIMI trial?

Accepted Answer

Saxagliptin

Answer

Saxagliptin (SAVOR-TIMI 53) was associated with a statistically significant increase in hospitalization for heart failure.

Question 3

A patient on warfarin for atrial fibrillation starts insulin glargine for newly diagnosed T2DM. What counseling point is most important?

Accepted Answer

Hypoglycemia can alter INR monitoring accuracy

Answer

Significant hypoglycemia can affect INR readings and alter hepatic metabolism, requiring closer anticoagulation monitoring.

Question 4

Which of the following statins carries the highest risk of myopathy due to drug interactions with CYP3A4 inhibitors?

Accepted Answer

Simvastatin

Answer

Simvastatin is extensively metabolized by CYP3A4, making it most susceptible to dose-dependent myopathy when combined with strong CYP3A4 inhibitors.

Question 5

A diabetic patient with prior MI and LDL of 85 mg/dL on high-intensity statin therapy asks if they need additional lipid-lowering therapy. According to ACC/AHA guidelines, what is the LDL target for very high-risk ASCVD patients?

Accepted Answer

Less than 70 mg/dL

Answer

ACC/AHA guidelines recommend an LDL goal of less than 70 mg/dL for very high-risk ASCVD patients, with ezetimibe or PCSK9 inhibitors added if needed.

(MTM) Medication Therapy Management Certification for Pharmacists Practice Test

(MTM) Medication Therapy Management Certification for Pharmacists Practice Test

MTM Diabetes & Cardiovascular Pharmacotherapy 3